The frequency of alterations, mutational spectrum, and clinical impact of IKZF1, PAX5, CDKN2A/2B, ERG gene mutations, and the IKZF1plus profile have not been extensively explored in Mexican pediatric B-ALL patients. This evidence concerns the gene PAX5 and acute lymphoblastic leukemia.